TICKERNERD
Menu
LBRXLBRXHealthcare · Biotechnology

LBRX Stock Forecast: LB Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$48
+0.74% on the day

The 8 Wall Street analysts covering LB Pharmaceuticals, Inc. hold a median 12-month price target of $49 — +3.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 6 of 100 as at 22 Aug 2026 — in the weakest quartile.

Market cap
$1.5B
Ticker Nerd rank
6 / 100
Median analyst target
$49
Analysts covering
8
Total return, dividends reinvested
1W
−0.4%
1M
+47.3%
YTD
+113.7%
From high
−2.8%
From low
+225.7%
$15
$49
Range since 11 Sept 2025, adjusted closes · the dot is the last close
Ticker Nerd rank

LBRX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores LB Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
6 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Value
59
Size
40
Quality
31
Momentum
31
Revisions
27
Issuance
17
Accruals
17
Growth
16
Volatility
4

Value (59): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.

Volatility (4): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

LBRX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LBRX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 11 Sept 2025Adjusted close, US dollars
$20$40$60$80Oct 25Jan 26Apr 26Jul 26LBRXHigh $78Median $49Low $37

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $37Median $49High $78

The green dot is the last close — the median target sits +3.0% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
12 Aug 2026BMO CapitalMaintainsOutperform$46 → $54
3 Aug 2026HC Wainwright & Co.ReiteratesBuy—
3 Aug 2026HC Wainwright & Co.ReiteratesBuy$45
21 July 2026BMO CapitalInitiatesOutperform$46
21 July 2026BMO CapitalInitiatesOutperform—
7 July 2026Wolfe ResearchInitiatesOutperform$45
7 July 2026Wolfe ResearchInitiatesOutperform—
27 Apr 2026HC Wainwright & Co.InitiatesBuy—
10 Apr 2026Craig-HallumInitiatesBuy—
27 Mar 2026StifelMaintainsBuy—
11 Dec 2025StifelMaintainsBuy—
6 Oct 2025Leerink PartnersInitiatesOutperform—
6 Oct 2025Piper SandlerInitiatesOverweight—
6 Oct 2025StifelInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LBRX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

LBRX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

LB Pharmaceuticals, Inc. (LBRX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−15.2×

Cheaper than 95% of US stocks

Price / sales
—
Price / book
4.1×

Cheaper than 26% of US stocks

EV / EBITDA
−13.3×

Cheaper than 86% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−50.0%

Higher than 21% of US stocks

Return on assets
−30.0%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LBRX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
LBRXLB Pharmaceuticals, Inc.$1.5B
6
TYRATyra Biosciences, Inc.$1.5B
34
INBXInhibrx Biosciences, Inc.$1.5B
26
BCAXBicara Therapeutics, Inc.$1.6B
50
INVAInnoviva, Inc.$1.6B
87
XERSXeris Biopharma Holdings, Inc.$1.6B
86
SLBTSL Science Holding Ltd.$1.5B
0

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own LB Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest LBRX news & analysis

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

Seeking Alpha · 17 Aug 2026positive

A Seeking Alpha article suggests biotech stocks, particularly small-cap names, may be the "comeback kid" of 2026, citing renewed optimism as macro and policy headwinds ease. The piece notes stabilisation at the FDA and a resurgence in M&A and IPO activity as restoring capital flows and investor confidence in the sector.

Why it matters — As a small-cap biotech, LBRX could be affected by the broader sector-wide rally, renewed capital flows, and improved FDA and M&A conditions described in the article.

LB Pharmaceuticals Announces $150 Million Private Placement

GlobeNewsWire · 29 July 2026neutral

LB Pharmaceuticals has entered into a securities purchase agreement to sell roughly 3.58 million shares of common stock and pre-funded warrants for about 715,500 shares to institutional investors in a private placement at $34.94 per share, raising $150 million.

Why it matters — The capital raise through a private placement provides LB Pharmaceuticals with additional funding to support its development and commercialization efforts, though it also dilutes existing shareholders.

FAQ

Frequently asked questions about LBRX stock

What is the LBRX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering LB Pharmaceuticals, Inc. have a median 12-month price target of $49, with estimates ranging from $37 to $78. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LBRX stock a buy right now?

Of the 8 analysts covering LB Pharmaceuticals, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks LB Pharmaceuticals, Inc. 6 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LBRX?

As at 22 Aug 2026, LB Pharmaceuticals, Inc. ranks 6 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (59 of 100).

Will LBRX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +3.0% from the last close, and Ticker Nerd's factor model ranks LB Pharmaceuticals, Inc. 6 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LBRX stock forecast for 2030?

No analyst covering LB Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LBRX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $37 to $78 over the next 12 months.

What does LB Pharmaceuticals, Inc. do?

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for neuropsychiatric diseases, with a particular emphasis on conditions such as schizophrenia and bipolar depression.

What is the latest news on LBRX?

The most recent item we track (Seeking Alpha, 17 Aug 2026): "Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes". A Seeking Alpha article suggests biotech stocks, particularly small-cap names, may be the "comeback kid" of 2026, citing renewed optimism as macro and policy headwinds ease. The piece notes stabilisation at the FDA and a resurgence in M&A and IPO activity as restoring capital flows and investor confidence in the sector.

Company

About LB Pharmaceuticals, Inc.

LB Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel therapies for neuropsychiatric diseases, with a particular emphasis on conditions such as schizophrenia and bipolar depression. The company’s primary focus lies in advancing its lead product candidate, LB-102, a chemically modified derivative of amisulpride—an established second-generation antipsychotic. LB-102 is designed to offer an improved therapeutic profile, aspiring to become the first benzamide antipsychotic approved for neuropsychiatric disorders in the United States. LB Pharmaceuticals builds its strategy on the extensive clinical experience with amisulpride and positive phase 2 clinical data for LB-102 in acute schizophrenia, aiming for further clinical development in both schizophrenia and bipolar depression. The company’s pipeline underscores its commitment to addressing unmet needs in mental health through innovative treatments. Founded in 2015 and headquartered in New York, LB Pharmaceuticals plays a notable role in the healthcare and biotechnology sectors by targeting disorders with significant societal impact and striving to set new standards in psychiatric care.

CEO Ms. Heather D. Turner Esq., J.D. · 49 employees · United States · https://lbpharma.us